İlaç onayları: Perjeta; Horizant; Iluven
Drug Approvals: Perjeta; Horizant; Iluvien
Genentech’s Herceptin, docetaxel combo Perjeta for the treatment of HER2-positive metastatic breast cancer, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease was approved by the FDA. GlaxoSmithKline and XenoPort said the FDA approved Horizant Extended-Release Tablets for the management of postherpetic neuralgia in adults. The approval means XenoPort is entitled to a milestone payment of $10 million from GSK. And Alimera Sciences said diabetic macular edema medicine Iluvien was approved in Portugal. Read more …
